Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating ...

Our analysis is essentially based on how ... between trends in earnings estimate revisions and short-term stock price movements. Pfizer is expected to post earnings of $0.67 per share for the ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher due to bleak growth and debt levels.

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...